Evidence map›Paper›PMID 38627457›Full record

ArticleNPJ breast cancer2024

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.

Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Stefania MorgantiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Qingchun JinDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6388-5123
Julie VincuillaBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Ryan BuehlerDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
Sean RyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Samantha StokesBroad Institute of MIT and Harvard, Boston, MA, USA.
Tonia ParkerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Elizabeth A MittendorfBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Tari A KingBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Anna WeissBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Ann H PartridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4722-4824
Brittany L BychkovskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7969-0603
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0003-1781-2518
Nabihah TayobHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6088-167X
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Judy E GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5940-8671
Filipa LynceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. filipa_lynce@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-6615-7076
Harvard University · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USBroad Institute · USDana-Farber Brigham Cancer Center · USUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.

Identifiers

PMID38627457
PMCPMC11021554
OpenAlexW4394841414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.